Literature DB >> 18322366

Basic research on dopamine in Parkinson's disease and the discovery of the nigrostriatal dopamine pathway: the view of an eyewitness.

Oleh Hornykiewicz1.   

Abstract

The article recapitulates some of the historical facts that led up to the recognition of dopamine (DA) as a biologically active substance in the brain and its crucial role in Parkinson's disease (PD). Three events to which the writer has been an eyewitness are specially highlighted and placed in their proper historical perspective: (1) the discovery of the striatal DA deficit in the PD brain; (2) the development of the DA replacement treatment with L-dopa, and (3) the 'birth' of the nigrostriatal DA pathway. The opposition to the new observations and their unexpected and far-reaching consequences will be illustrated by briefly discussing the strongly negative opinions expressed by some famous brain scientists of the day about the relationship between the substantia nigra, PD, and the DA-containing nigrostriatal fiber connection. 2008 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18322366     DOI: 10.1159/000113678

Source DB:  PubMed          Journal:  Neurodegener Dis        ISSN: 1660-2854            Impact factor:   2.977


  24 in total

1.  Environmental neurotoxin-induced progressive model of parkinsonism in rats.

Authors:  Wei-Bin Shen; Kimberly A McDowell; Aubrey A Siebert; Sarah M Clark; Natalie V Dugger; Kimberly M Valentino; H A Jinnah; Carole Sztalryd; Paul S Fishman; Christopher A Shaw; M Samir Jafri; Paul J Yarowsky
Journal:  Ann Neurol       Date:  2010-07       Impact factor: 10.422

2.  Calpain inhibition protected spinal cord motoneurons against 1-methyl-4-phenylpyridinium ion and rotenone.

Authors:  S Samantaray; V H Knaryan; C Le Gal; S K Ray; N L Banik
Journal:  Neuroscience       Date:  2011-06-22       Impact factor: 3.590

Review 3.  Tracking extranigral degeneration in animal models of Parkinson's disease: quest for effective therapeutic strategies.

Authors:  Varduhi H Knaryan; Supriti Samantaray; Charlene Le Gal; Swapan K Ray; Naren L Banik
Journal:  J Neurochem       Date:  2011-06-17       Impact factor: 5.372

Review 4.  Dopamine D1 receptors, regulation of gene expression in the brain, and neurodegeneration.

Authors:  Jean Lud Cadet; Subramaniam Jayanthi; Michael T McCoy; Genevieve Beauvais; Ning Sheng Cai
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-11       Impact factor: 4.388

Review 5.  Metabolic hormones, dopamine circuits, and feeding.

Authors:  Nandakumar S Narayanan; Douglas J Guarnieri; Ralph J DiLeone
Journal:  Front Neuroendocrinol       Date:  2009-10-28       Impact factor: 8.606

Review 6.  The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia.

Authors:  Walter J Schulz-Schaeffer
Journal:  Acta Neuropathol       Date:  2010-06-20       Impact factor: 17.088

7.  SNJ-1945, a calpain inhibitor, protects SH-SY5Y cells against MPP(+) and rotenone.

Authors:  Varduhi H Knaryan; Supriti Samantaray; Sookyoung Park; Mitsuyoshi Azuma; Jun Inoue; Naren L Banik
Journal:  J Neurochem       Date:  2013-12-16       Impact factor: 5.372

Review 8.  Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disorders.

Authors:  David S Goldstein; Irwin J Kopin; Yehonatan Sharabi
Journal:  Pharmacol Ther       Date:  2014-06-16       Impact factor: 12.310

9.  Mapping dopaminergic projections in the human brain with resting-state fMRI.

Authors:  Koen V Haak; Christian F Beckmann; Marianne Oldehinkel; Alberto Llera; Myrthe Faber; Ismael Huertas; Jan K Buitelaar; Bastiaan R Bloem; Andre F Marquand; Rick C Helmich
Journal:  Elife       Date:  2022-02-03       Impact factor: 8.140

10.  Chronic methamphetamine administration causes differential regulation of transcription factors in the rat midbrain.

Authors:  Irina N Krasnova; Bruce Ladenheim; Amber B Hodges; Nora D Volkow; Jean Lud Cadet
Journal:  PLoS One       Date:  2011-04-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.